Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a **combination allergen extract** used in allergen immunotherapy for the treatment or prevention of allergic rhinitis and/or conjunctivitis in patients sensitized to grass pollens (6-grass blend), house dust mite (dermatophagoides pteronyssinus), birch pollen, and mugwort pollen. Allergen immunotherapy functions by administering controlled amounts of allergens over time, aiming to induce immune tolerance and reduce allergic symptoms. Clinical studies confirm efficacy and safety for individual components such as standardized grass pollen mixtures[7], birch pollen extract[2][4][6], and house dust mite extract in sublingual and injectable immunotherapy for IgE-mediated allergic conditions. Mechanistically, the treatment works by modulating the immune response to decrease allergen-specific IgE and increase blocking IgG4 antibody levels, reducing symptom severity and medication need during relevant pollen seasons[7][4][2][6]. The combination is generally administered via sublingual or subcutaneous route, often following standardized protocols.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-grass pollen mixture extract + dermatophagoides pteronyssinus extract + birch pollen extract + mugwort pollen extract.